

**Question for written answer E-006839/2020
to the Commission**

Rule 138

Marc Botenga (GUE/NGL)

Subject: EU funding and support for research, development and innovation regarding health technologies

EU funds play a crucial role in funding health-related research, development and innovation. Some programmes, like the Innovative Medicines Initiative, were specifically designed for this purpose. Others, like Horizon 2020 or, in a different way, the European Fund for Strategic Investment and the 2021-2027 InvestEU, have clearly contributed significantly to the development of health technologies. The COVID-19 crisis has further boosted EU funding in this area.

1. Can the Commission quantify, across the relevant programmes, how much EU funding went into research, development and innovation in the field of health technologies, and more specifically medicines and vaccines, between 2014 and 2020, including COVID-19-specific funding?
2. Can the Commission quantify, across the relevant programmes, how much EU funding went into research, development and innovation in the field of health technologies, and more specifically medicines and vaccines, between 2014 and 2020, excluding COVID-19-specific funding?
3. Can the Commission provide an overview of what proportion of this funding went to public entities and institutions, private actors and public-private partnerships respectively?